Provided by Tiger Trade Technology Pte. Ltd.

Iovance Biotherapeutics, Inc.

10.15
+0.28012.84%
Volume:17.00M
Turnover:179.40M
Market Cap:4.60B
PE:-14.38
High:10.98
Open:10.26
Low:10.12
Close:9.87
52wk High:10.98
52wk Low:1.76
Shares:452.97M
Float Shares:394.00M
Volume Ratio:1.47
T/O Rate:4.32%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7058
EPS(LYR):-1.0941
ROE:-40.36%
ROA:-20.31%
PB:6.25
PE(LYR):-9.28

Loading ...

May 13, 2022

Major Issues Report

8-K - Current report
May 05, 2022

Major Issues Report

8-K - Current report
May 05, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Apr 29, 2022

Major Issues Report

8-K - Current report
Apr 05, 2022

Major Issues Report

8-K - Current report
Mar 11, 2022

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Feb 24, 2022

Major Issues Report

8-K - Current report
Feb 24, 2022

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 14, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 11, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 10, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 04, 2022

Beneficial Ownership Change

SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 04, 2022

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 19, 2022

Major Issues Report

8-K - Current report
Jan 10, 2022

Major Issues Report

8-K - Current report
Nov 04, 2021

Major Issues Report

8-K - Current report
Nov 04, 2021

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Sep 23, 2021

Major Issues Report

8-K - Current report
Sep 23, 2021

Employee Stock Ownership

S-8 - Securities to be offered to employees in employee benefit plans
Aug 05, 2021

Major Issues Report

8-K - Current report